Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 6, 2002, Pages 638-647

  Klein, Cheri Enders ^a,b   Gupta, Elora ^a,b   Reid, Joel M ^a,b   Atherton, Pamela J ^a,b   Sloan, Jeff A ^a,b   Pitot, Henry C ^a,b   Ratain, Mark J ^a,b   Kastrissios, Helen ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; DRUG METABOLITE; GLUCURONIDE; IRINOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COLORECTAL CANCER; COMPARTMENT MODEL; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; FEMALE; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLUBILITY;

ADULT; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BILIRUBIN; CAMPTOTHECIN; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GLUCURONATES; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; OXIDOREDUCTASES; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 0036908854     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.129502     Document Type: Article

References (38)

1. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000;60:1189-92.
2. Tsuji T, Kaneda N, Kado K, Yokokura T, Yoshimoto T, Tsuru D. CPT-11 converting enzyme from rat serum: Purification and some properties. J Pharmacobiodyn 1991;14:341-9.
3. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847-54.
4. Ciotti M, Basu N, Brangi M, Owens IS. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999;260:199-202.
5. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following IV infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos 2000;28:423-33.
6. Haaz M-C, Rivory L, Riche C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998;58:468-72.
7. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commercon A, et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996;56:3689-94.
8. Kawato Y, Furuta T, Aonuma M, Yasuoka M, Yokokura T, Matsumoto K. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991;28:192-8.
9. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
10. Gupta E, Lestingi T, Mick R, Ramirez J, Vokes E, Ratain M. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 1994;54:3723-5.
11. Gupta E, Mick R, Ramirez J, Wang X, Lestingi T, Vokes E, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997;15:1502-10.
12. Yamamoto N, Tamura T, Karato A, Uenaka K, Eguchi K, Shinkai T, et al. CPT-11: Population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian model in patients with lung cancer. Jpn J Cancer Res 1994;85:972-7.
13. Chabot G. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother Pharmacol 1995;36:463-72.
14. Canal P, Gay C, Dezeuze A, Douillard J, Bugat R, Brunet R, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996;14:2688-95.
15. Rivory L, Haaz M-C, Canal P, Lokiec F, Armand J-P, Robert J. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997;3:1261-6
16. Sparreboom A, de Jonge M, de Bruijn P, Brouwer E, Nooter K, Loos W, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998;4:2747-54.
17. Chabot G, Abigerges D, Catimel G, Culine S, de Forni M, Extra J, et al. Population pharmacokinetics and pharmaco-dynamics of irinotecan (CPT-II) and active metabolite SN-38 during phase I trials. Ann Oncol 1995;6:141-51
18. Herbert V, Schellens J, Swart M, Gruia G, Vernillet L, Beijnen J, et al. Phase I and pharmacokinetics study of irinotecan administered as a low-dose, continuous intra-venous infusion over 14 days in patients with malignant solid tumors. J Clin Oncol 1999;17:1897-905
19. Lhomme C, Fumoleau P, Fargeot P, Krakowski Y, Dieras V, Chauvergne J, et al. Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999;17:3136-42.
20. Chabot G. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997;33:245-59.
21. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 2000;6:2236-44.
22. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55
23. Beal SL, Sheiner LB, editors. NONMEM Users Guide. Part 1. Users Basic Guide. 5th Ed. San Francisco: NON-MEM Project Group, Univ. of California at San Francisco; 1992.
24. Beal SL, Sheiner LB, editors. NONMEM Users Guide. Part VII. Conditional Estimation Methods 5th Ed. San Francisco: NONMEM Project Group, Univ. of California at San Francisco; 1992.
25. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic - Pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992;20:511-28.
26. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977;5:445-79.
27. Rivory L, Bowles M, Robert J, Pond S. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996;52:1103-11.
28. Dodds HM, Clarke SJ, Findlay M, Bishop JF, Robert J, Rivory LP. Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance. Cancer Chemother Pharmacol 2000;45:9-14.
29. Combes O, Barre J, Duche JC, Vernillet L, Archimbaud Y, Marietta MP, et al. In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood. Invest New Drugs 2000;18:1-5.
30. Zhu W, Song L, Zhang H, Matoney L, LeCluyse E, Yan B. Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab Dispos 2000;28:186-91.
31. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998;92:73-82.
32. Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998;23:247-55.
33. Miya T, Goya T, Fujii H, Ohtsu T, Itoh K, Igarashi T, et al. Factors affecting the pharmacokinetics of CPT-11: The body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest New Drugs 2001;19:61-7.
34. Guichard S, Terret C, Hennebelle I, Lochon I, Chervreau P, Fretigny E, et al. CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues. Br J Cancer 1999;80:364-70.
35. Haaz MC, Rivory LP, Riche C, Robert J. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol 1997;356:257-62.
36. Huang L, Vore M. Multidrug resistance p-glycoprotein 2 is essential for the biliary excretion of indocyanine green. Drug Metab Dispos 2001;29:634-7.
37. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999;65:576-82.
38. Iyer L, Janisch L, Das S, Ramirez J, Hurley-Buterman C, DeMario M, et al. UGT1A1 promoter genotype correlates with pharmacokinetics of irinotecan (CPT-11) [abstract]. Proc Am Soc Clin Oncol 2000:690.